Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis.
Inflammatory bowel disease (IBD) is a chronic inflammatory gastrointestinal disorder. Systemic treatment of IBD patients with anti-tumor necrosis factor (TNF)-alpha antibodies has proven to be a highly promising approach, but several drawbacks remain, including side effects related to systemic administration and high cost of treatment. Lactococcus lactis was engineered to secrete monovalent and bivalent murine (m)TNF-neutralizing Nanobodies as therapeutic proteins. These therapeutic proteins are derived from fragments of heavy-chain camelid antibodies and are more stable than conventional antibodies. L. lactis-secreted anti-mTNF Nanobodies neutralized mTNF in vitro. Daily oral administration of Nanobody-secreting L. lactis resulted in local delivery of anti-mTNF Nanobodies at the colon and significantly reduced inflammation in mice with dextran sulfate sodium (DSS)-induced chronic colitis. In addition, this approach was also successful in improving established enterocolitis in interleukin 10 (IL10)(-/-) mice. Finally, L. lactis-secreted anti-mTNF Nanobodies did not interfere with systemic Salmonella infection in colitic IL10(-/-) mice.In conclusion, this report details a new therapeutic approach for treatment of chronic colitis, involving in situ secretion of anti-mTNF Nanobodies by orally administered L. lactis bacteria. Therapeutic application of these engineered bacteria could eventually lead to more effective and safer management of IBD in humans.
Department for Molecular Biomedical Research, VIB, Zwijnaarde, Belgium.
K
K
Vandenbroucke
H
H
de Haard
E
E
Beirnaert
T
T
Dreier
M
M
Lauwereys
L
L
Huyck
J
J
Van Huysse
P
P
Demetter
L
L
Steidler
E
E
Remaut
C
C
Cuvelier
P
P
Rottiers
D000284:Administration, Oral; D000818:Animals; D018033:Antibodies, Bispecific / Q000008:administration & dosage / Q000235:genetics; D002460:Cell Line; D002908:Chronic Disease; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D016264:Dextran Sulfate / Q000008:administration & dosage; D005260:Female; D005818:Genetic Engineering; D013294:Lactococcus lactis / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D053758:Nanoparticles / Q000008:administration & dosage; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D018033:Antibodies, Bispecific; D014409:Tumor Necrosis Factor-alpha; D016264:Dextran Sulfate